GLP-1
Pemvidutide 2026: The GLP-1/Glucagon Dual Agonist Rewriting MASH and Weight Loss Treatment
Pemvidutide earned FDA Breakthrough Therapy Designation for MASH in January 2026, with 59.1% biopsy-confirmed MASH resolution and best-in-class 21.9% lean mass loss during weight reduction.